Clinical trial
Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
NCT03111901 is registered in ClinicalTrials.gov with William Grosh, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
- Lead sponsor
- William Grosh, MD
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- October 29, 2018
- Completion date
- October 31, 2023
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.